# Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

> **NCT03128411** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 64 (actual)

## Conditions studied

- Leukemia, Chronic Myelogenous

## Interventions

- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT03128411
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2019-03-12
- **Final completion:** 2021-03-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03128411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03128411, "Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03128411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*